Positive News SentimentPositive NewsNASDAQ:QNRX Quoin Pharmaceuticals (QNRX) Stock Price, News & Analysis $5.16 -0.02 (-0.39%) Closing price 03:49 PM EasternExtended Trading$4.92 -0.24 (-4.57%) As of 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Quoin Pharmaceuticals Stock (NASDAQ:QNRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Quoin Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.66▼$5.1850-Day Range$3.25▼$6.0552-Week Range$3.25▼$41.80Volume33,858 shsAverage Volume135,857 shsMarket Capitalization$10.37 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Read More Quoin Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreQNRX MarketRank™: Quoin Pharmaceuticals scored higher than 13% of companies evaluated by MarketBeat, and ranked 860th out of 918 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingHold Consensus RatingQuoin Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Amount of Analyst CoverageQuoin Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Quoin Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Quoin Pharmaceuticals is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quoin Pharmaceuticals is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuoin Pharmaceuticals has a P/B Ratio of 2.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Quoin Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.24% of the float of Quoin Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverQuoin Pharmaceuticals has a short interest ratio ("days to cover") of 4.43.Change versus previous monthShort interest in Quoin Pharmaceuticals has recently decreased by 3.91%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQuoin Pharmaceuticals does not currently pay a dividend.Dividend GrowthQuoin Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment1.87 News SentimentQuoin Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Quoin Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for QNRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Quoin Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders11.17% of the stock of Quoin Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions8.63% of the stock of Quoin Pharmaceuticals is held by institutions.Read more about Quoin Pharmaceuticals' insider trading history. Receive QNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quoin Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QNRX Stock News HeadlinesQNRX: Believe Conditional FDA Approval of Proposed Brand Name Reflects QRX003 Nearing Potential Commercialization40 minutes ago | finance.yahoo.comQuoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial ResultsAugust 14, 2026 | globenewswire.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.August 27 at 1:00 AM | The Oxford Club (Ad)Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026August 7, 2026 | globenewswire.comQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin SyndromeJuly 9, 2026 | finanznachrichten.deQuoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin SyndromeJuly 9, 2026 | globenewswire.comQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton SyndromeJune 30, 2026 | finanznachrichten.deQuoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton SyndromeJune 30, 2026 | globenewswire.comSee More Headlines QNRX Stock Analysis - Frequently Asked Questions How have QNRX shares performed this year? Quoin Pharmaceuticals' stock was trading at $14.43 at the beginning of the year. Since then, QNRX shares have decreased by 64.2% and is now trading at $5.16. How were Quoin Pharmaceuticals' earnings last quarter? Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) announced its earnings results on Friday, August, 14th. The company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($1.61) by $0.29. When did Quoin Pharmaceuticals' stock split? Shares of Quoin Pharmaceuticals reverse split on the morning of Monday, July 17th 2023.The 1-12 reverse split was announced on Monday, July 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did Quoin Pharmaceuticals IPO? Quoin Pharmaceuticals (QNRX) raised $0 in an IPO on Friday, July 29th 2016. The company issued 1,292,308 shares at a price of $0.00 per share. Who are Quoin Pharmaceuticals' major shareholders? Quoin Pharmaceuticals' top institutional shareholders include Velan Capital Investment Management LP (1.61%). Insiders that own company stock include Denise P Carter, Gordon Dunn, Anthony James Culverwell and Michael Myers. View institutional ownership trends. How do I buy shares of Quoin Pharmaceuticals? Shares of QNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quoin Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quoin Pharmaceuticals investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Zomedica (ZOM) and Abbott Laboratories (ABT). Company Calendar Last Earnings8/14/2026Today8/27/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 2 weeks, QNRX's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:QNRX CIK1671502 Webquoinpharma.com Phone(703) 980-4182Fax972-9767-8750Employees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)($25.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.81 million Net MarginsN/A Pretax MarginN/A Return on Equity-489.57% Return on Assets-221.17% Debt Debt-to-Equity RatioN/A Current Ratio1.76 Quick Ratio1.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.96 per share Price / Book2.63Miscellaneous Outstanding Shares2,010,000Free Float1,784,000Market Cap$10.37 million OptionableNot Optionable Beta1.50 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:QNRX) was last updated on 8/27/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quoin Pharmaceuticals, Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Quoin Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
